APX001 and Other Gwt1 Inhibitor Prodrugs Are Effective in Experimental Coccidioides immitis Pneumonia
AAC 2019 Viriyakosol
APX001 Is Effective in the Treatment of Murine Invasive Pulmonary Aspergillosis
AAC 2019 Gebremariam
APX001 Pharmacokinetic/Pharmacodynamic Target Determination against Aspergillus fumigatus in an in vivo Model of Invasive Pulmonary Aspergillosis.
AAC 2019 Zhao
In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model
AAC 2018 Zhao
Significantly Improved Pharmacokinetics Enhances In Vivo Efficacy of APX001 against Echinocandin- and Multidrug Resistant Candida Isolates in a Mouse Model of Invasive Candidiasis
AAC 2018 Zhao
APX001A In Vitro Activity against Contemporary Blood Isolates and Candida auris Determined by the EUCAST Reference Method.
AAC 2018 Arendrup
In Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris
AAC 2018 Hager
In Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus
AAC 2018 Shaw
In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model
AAC 2018 Zhao
The Investigational Agent E1210 Is Effective in Treatment of Experimental Invasive Candidiasis Caused by Resistant Candida albicans
AAC 2015 Wiederhold
E1210, a New Broad-Spectrum Antifungal, Suppresses Candida albicans Hyphal Growth through Inhibition of Glycosylphosphatidylinositol Biosynthesis
AAC 2012 Watanabe
Efficacy of Oral E1210, a New Broad-Spectrum Antifungal with a Novel Mechanism of Action, in Murine Models of Candidiasis, Aspergillosis, and Fusariosis
AAC 2012 Hata
In Vitro Activity of E1210, a Novel Antifungal, against Clinically Important Yeasts and Molds
AAC 2011 Miyazaki